Next Article in Journal
Prevalence and Correlates of Preschool Overweight and Obesity Amidst the Nutrition Transition: Findings from a National Cross-Sectional Study in Lebanon
Next Article in Special Issue
Copper to Zinc Ratio as Disease Biomarker in Neonates with Early-Onset Congenital Infections
Previous Article in Journal
Prevalence of Vitamin D Deficiency and Its Associations with Skin Color in Pregnant Women in the First Trimester in a Sample from Switzerland
Open AccessArticle

Chondroprotective Effects of Ginsenoside Rg1 in  Human Osteoarthritis Chondrocytes and a Rat Model  of Anterior Cruciate Ligament Transection

Department of Orthopedics, The Second Hospital of Anhui Medical University, No. 678 Furong Road, Hefei 230601, China
Department of Orthopedics, Lu’an People’s Hospital Affiliated to Anhui Medical University, Lu’an 237000, China
Department of Orthopedics, The Peoples Hospital of Luhe Affiliated to Yangzhou University Medical Academy, Nanjing 211500, China
Department of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, No. 99 Huaihai West Road, Xuzhou 221000, China
Department of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing 210029, China
Authors to whom correspondence should be addressed.
Nutrients 2017, 9(3), 263;
Received: 13 December 2016 / Accepted: 3 March 2017 / Published: 10 March 2017
(This article belongs to the Special Issue Nutrients, Infectious and Inflammatory Diseases)
This study aimed to assess whether Ginsenoside Rg1 (Rg1) inhibits inflammatory responses in human chondrocytes and reduces articular cartilage damage in a rat model of osteoarthritis (OA). Gene expression and protein levels of type II collagen, aggrecan, matrix metalloproteinase (MMP)‐13 and cyclooxygenase‐2 (COX‐2) were determined in vitro by quantitative real‐time‐polymerase chain reaction and Western blotting. Prostaglandin E2 (PGE2) amounts in the culture medium were determined by enzyme‐linked immunosorbent assay (ELISA). For in vivo assessment, a rat model of OA was generated by anterior cruciate ligament transection (ACLT). Four weeks after ACLT, Rg1 (30 or 60 mg/kg) or saline was administered by gavage once a day for eight consecutive weeks. Joint damage was analyzed by histology and immunohistochemistry. Ginsenoside Rg1 inhibited Interleukin (IL)‐1β‐induced chondrocyte gene and protein expressions of MMP‐13, COX‐2 and PGE2, and prevented type II collagen and aggrecan degradation, in a dose‐dependent manner. Administration of Ginsenoside Rg1 to OA rats attenuated cartilage degeneration, and reduced type II collagen loss and MMP‐13 levels. These findings demonstrated that Ginsenoside Rg1 can inhibit inflammatory responses in human chondrocytes in vitro and reduce articular cartilage damage in vivo, confirming the potential therapeutic value of Ginsenoside Rg1 in OA. View Full-Text
Keywords: ginsenoside‐Rg1; osteoarthritis; chondrocyte ginsenoside‐Rg1; osteoarthritis; chondrocyte
Show Figures

Figure 1

MDPI and ACS Style

Cheng, W.; Jing, J.; Wang, Z.; Wu, D.; Huang, Y. Chondroprotective Effects of Ginsenoside Rg1 in  Human Osteoarthritis Chondrocytes and a Rat Model  of Anterior Cruciate Ligament Transection. Nutrients 2017, 9, 263.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop